A Phase II, Open-Label, Multicenter, Escalating Dose, Study to Determine Pharmacokinetic and Pharmacodynamic Profile of Dexmedetomidine in Pediatric Subjects Ages ≥ 2 Through < 17 Years Old
Latest Information Update: 18 Apr 2017
Price :
$35 *
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Pain
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Hospira
- 16 Jun 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 16 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jan 2009 Status changed from not yet recruiting to recruiting.